Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease [PDF]
Качественная клиническая практика, 2018 Aim. Evaluation of the impact on the budget of the program for the provision of necessary medications (ONLS program) for the inclusion of a new drug vedolizumab for the treatment of adult patients with moderate or severe active ulcerative colitis (UC ...
S. K. Zyryanov +3 more
doaj +3 more sources
Vedolizumab for inflammatory bowel diseasesI [PDF]
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018 Aim of review. To present literature data on administration of vedolizumab at inflammatory bowel diseases. Summary. The vedolizumab is anti-α4β7-integrin humanized class IgG1 antibodies which suppresses migration of leukocytes in intestinal tissue ...
Igor L. Khalif, M. V. Shapina
doaj +3 more sources
Modern Approaches to Vaccination of Patients with Chronic Liver Diseases and Inflammatory Bowel Diseases against a Novel Coronavirus Infection [PDF]
, 2022 Aim. To analyze the literature data on the peculiarities of vaccination of patients with chronic liver diseases (CLD) and inflammatory bowel diseases (IBD) against COVID-19 infection.Key findings.
A. A. Sheptulin, V. T. Ivashkin
core +2 more sources
Clinical Remission and Mucosal Healing in Patients with Ulcerative Colitis Undergoing Treatment with Tofacitinib: A Two-Year Follow-Up [PDF]
, 2022 Ulcerative colitis is a chronic mucosal inflammatory disease of the colon with clinical manifestations of bleeding, diarrhea, and abdominal pain.
Petrova, Asiyana
core +2 more sources
Исходы новой коронавирусной инфекции COVID-19 у 68 пациентов с воспалительными заболеваниями кишечника [PDF]
, 2020 Background. COVID-19 is an infectious respiratory syndrome with a wide range of manifestations and outcomes. Patients with inflammatory bowel disease (IBD) generally have a higher risk of infection, especially if they receive immunosuppressive therapy ...
Chernova M.E. +10 more
core +2 more sources
Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies [PDF]
, 2023 Background. Primary immunodeficiencies (PIDs), now known as inborn errors of immunity, are a group of inherited diseases caused by defects in the genes that control the immune response.
Alexander V. Karaulov +11 more
core +2 more sources
Course of COVID-19 in Patients with Inflammatory Bowel Disease: Regional Experience [PDF]
, 2022 Aim: to study the course of COVID-19 in patients with inflammatory bowel diseases (IBD) using the example of the region of the Republic of Tatarstan.Material and methods.
A. Kh. Odintsova +6 more
core +2 more sources
Features of Crohn's Disease Depending on the Age of Disease Onset [PDF]
, 2023 Aim: to evaluate the characteristics of Crohn's disea depending on the age of the disease onset in patients observed in a specialized City Center for Inflammatory Bowel Diseases Diagnosis and Treatment.Materials and methods. We observed 180 patients with
E. G. Ganich, O. B. Shchukina
core +2 more sources
АНАЛИЗ ВЛИЯНИЯ НА БЮДЖЕТ ПРИМЕНЕНИЯ БИОЛОГИЧЕСКИХ ПРЕПАРАТОВ В ТЕРАПИИ ВЗРОСЛЫХ ПАЦИЕНТОВ С ЯЗВЕННЫМ КОЛИТОМ И БОЛЕЗНЬЮ КРОНА [PDF]
, 2017 Aims of the study: to assess health care costs of the use of biological agents (vedolizumab and various TNF-α inhibitors) in adult patients with moderate to severe active ulcerative colitis (UC) and moderate or severe active Crohn’s disease (CT) with an ...
E. Pyadushkina A. +1 more
core +2 more sources
Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria) [PDF]
, 2023 In recent years, there has been a significant increase in the number of patients with malignancies treated with immune checkpoint inhibitors (ICIs), including the anti-programmed cell death protein 1 (anti–PD-1) agent pembrolizumab.
A. V. Snegovoy +8 more
core +2 more sources